BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Balstilimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Balstilimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05205330-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Balstilimab: Phase 1/2 readout est. (NCT05205330)
DESCRIPTION:Balstilimab\, phase 1/2.\nStudy: Vorbipiprant (CR6086) / Balsti
 limab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC\, and O
 ther Metastatic GI Cancers\nEstimated primary completion: December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/balstilimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05205330
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06300463-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Balstilimab: Phase 2 readout est. (NCT06300463)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: Platform Study of Immunotherapy 
 Combinations in Colorectal Cancer Liver Metastases\nEstimated primary comp
 letion: December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/balstilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06300463
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128355-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Balstilimab: Phase 1 readout est. (NCT07128355)
DESCRIPTION:Balstilimab\, phase 1.\nStudy: Botensilimab\, Balstilimab\, and
  SBRT in Colorectal Cancer\nEstimated primary completion: 1 January 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/balstilimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07128355
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06336902-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Balstilimab: Phase 1 readout est. (NCT06336902)
DESCRIPTION:Balstilimab\, phase 1.\nStudy: Botensilimab Plus Balstilimab an
 d Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Meta
 static Colorectal Cancer\nEstimated primary completion: 15 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/balstilimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06336902
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04028063-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Balstilimab: Phase 2 readout est. (NCT04028063)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: Doxorubicin Plus Dual Checkpoint
  Blockade for Soft Tissue Sarcomas\nEstimated primary completion: 7 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/balstilimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0402806
 3
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845450-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Balstilimab: Phase 2 readout est. (NCT05845450)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: Pre-operative Targeted Treatment
 s in Molecularly Selected Resectable Colorectal Cancer (UNICORN)\nEstimate
 d primary completion: May 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/balstilimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05845450
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07735624-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Balstilimab: Phase 2 readout est. (NCT07735624)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: RECTIFY-1: Neoadjuvant Botensili
 mab + Balstilimab in MSS/pMMR Early Rectal Cancer\nEstimated primary compl
 etion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 alstilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07735624
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05627635-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20270616
DTEND;VALUE=DATE:20270617
SUMMARY:Balstilimab: Phase 1/2 readout est. (NCT05627635)
DESCRIPTION:Balstilimab\, phase 1/2.\nStudy: FOLFOX and Bevacizumab in Comb
 ination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of
  Microsatellite Stable (MSS) Metastatic Colorectal Cancer\nEstimated prima
 ry completion: 16 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/balstilimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05627635
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589440-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Balstilimab: Phase 2 readout est. (NCT06589440)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: Phase 2 Study of SR-8541A in Com
 bination With Botensilimab and Balstilimab in Subjects With Refractory Met
 astatic Microsatellite Stable Colorectal Cancer (MSS-CRC)\nEstimated prima
 ry completion: 31 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/balstilimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06589440
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06251973-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Balstilimab: Phase 2 readout est. (NCT06251973)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: A Study of agenT-797 in Combinat
 ion With Botensilimab\, Balstilimab\, Ramucirumab\, and Paclitaxel for Peo
 ple With Esophageal\, Gastric\, or Gastro-esophageal Junction Cancer\nEsti
 mated primary completion: 1 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/balstilimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06251973
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05608044-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Balstilimab: Phase 2 readout est. (NCT05608044)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: A Study of Botensilimab and Bals
 tilimab for the Treatment of Colorectal Cancer\nEstimated primary completi
 on: September 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 alstilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05608044
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782555-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Balstilimab: Phase 1/2 readout est. (NCT06782555)
DESCRIPTION:Balstilimab\, phase 1/2.\nStudy: A Study of Evofosfamide in Com
 bination With Zalifrelimab and Balstilimab\nEstimated primary completion: 
 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/balstil
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06782555
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780787-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:Balstilimab: Phase 2 readout est. (NCT06780787)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: FOLFOX\, Botensilimab\, and Bals
 tilimab for the Treatment of Localized Rectal Cancer Before Surgery\nEstim
 ated primary completion: 5 November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/balstilimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06780787
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843434-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20280220
DTEND;VALUE=DATE:20280221
SUMMARY:Balstilimab: Phase 2 readout est. (NCT06843434)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: A Study of Botensilimab and Bals
 tilimab for Rectal Adenocarcinoma\nEstimated primary completion: 20 Februa
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/balstilimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0684
 3434
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07193862-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:Balstilimab: Phase 1 readout est. (NCT07193862)
DESCRIPTION:Balstilimab\, phase 1.\nStudy: Pilot Study of an Implantable Mi
 crodevice for In Situ Evaluation of Drug Response in Patients With Colorec
 tal Liver Metastasis\nEstimated primary completion: 15 April 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/balstilimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07193862
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06346197-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20280515
DTEND;VALUE=DATE:20280516
SUMMARY:Balstilimab: Phase 3 readout est. (NCT06346197)
DESCRIPTION:Balstilimab\, phase 3.\nStudy: Combination of Immune Checkpoint
  in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas\nEs
 timated primary completion: 15 May 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/balstilimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06346197
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268015-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Balstilimab: Phase 2 readout est. (NCT06268015)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: Botensilimab and Balstilimab Opt
 imization in Colorectal Cancer\nEstimated primary completion: July 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/balstilimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06268015
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550088-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Balstilimab: Phase 2 readout est. (NCT07550088)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: BAL/BOT/agenT-797 in pMMR CRC Wi
 th Liver Metastases\nEstimated primary completion: September 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/balstilimab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07550088
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782932-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Balstilimab: Phase 1/2 readout est. (NCT06782932)
DESCRIPTION:Balstilimab\, phase 1/2.\nStudy: Comparing Neoadjuvant/Adjuvant
  GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Res
 ectable Pancreatic Cancer\nEstimated primary completion: December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/balstilimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06782932
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07595874-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20281216
DTEND;VALUE=DATE:20281217
SUMMARY:Balstilimab: Phase 2 readout est. (NCT07595874)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: Neoadjuvant Botensilimab and Bal
 stilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3\
 nEstimated primary completion: 16 December 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/balstilimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07595874
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516366-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Balstilimab: Phase 2 readout est. (NCT07516366)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: Testing the Safety and Feasibili
 ty of Immunotherapy Drugs\, Botensilimab and Balstilimab\, Before Surgery 
 for Clear Cell Renal Cell Carcinoma\, NEO RoBOT Trial\nEstimated primary c
 ompletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/balstilimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07516366
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06279130-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Balstilimab: Phase 2/3 readout est. (NCT06279130)
DESCRIPTION:Balstilimab\, phase 2/3.\nStudy: Pan-tumor Neoadjuvant Basket S
 tudy of Immune Check-point Inhibition and Novel Immuno-oncology Combinatio
 ns\nEstimated primary completion: 29 January 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/balstilimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06279130
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551596-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20290828
DTEND;VALUE=DATE:20290829
SUMMARY:Balstilimab: Phase 2 readout est. (NCT07551596)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: Testing the Combination of Anti-
 Cancer Drugs\, Botensilimab (AGEN1181) and Balstilimab (AGEN2034)\, After 
 Standard Treatment for Colorectal Cancer\, Combat Trial\nEstimated primary
  completion: 28 August 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/balstilimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07551596
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05891821-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Balstilimab: Phase 2 readout est. (NCT05891821)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: Assessment of the Safety and Eff
 icacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (I
 MMONC0001)\nEstimated primary completion: September 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/balstilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05891821
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06411691-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Balstilimab: Phase 1 readout est. (NCT06411691)
DESCRIPTION:Balstilimab\, phase 1.\nStudy: KRAS-Targeted Vaccine Combined W
 ith Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorect
 al Cancer and Pancreatic Ductal Cancer\nEstimated primary completion: 1 No
 vember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/balstili
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06411691
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06322108-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Balstilimab: Phase 2 readout est. (NCT06322108)
DESCRIPTION:Balstilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ass
 essment of the Safety and Efficacy of Balstilimab in Combination With Bote
 nsilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)\nEst
 imated primary completion: April 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/balstilimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06322108
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06843551-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20300801
DTEND;VALUE=DATE:20300802
SUMMARY:Balstilimab: Phase 2 readout est. (NCT06843551)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: The Miami "EMPIRE" Trial - Eradi
 cation of Metastatic Pancreatic Cancer With Immuno-Radiation\nEstimated pr
 imary completion: 1 August 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/balstilimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06843551
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227636-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Balstilimab: Phase 2 readout est. (NCT07227636)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: A Study of Botensilimab and Bals
 tilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy\n
 Estimated primary completion: November 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/balstilimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07227636
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05864534-2380@assetmemo.bio
DTSTAMP:20261121T005831Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Balstilimab: Phase 2 readout est. (NCT05864534)
DESCRIPTION:Balstilimab\, phase 2.\nStudy: Phase 2a Immune Modulation With 
 Ultrasound for Newly Diagnosed Glioblastoma\nEstimated primary completion:
  31 July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/balsti
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05864534
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
